Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.33 ▼ +0.00
(-0.78%)
MKT CAP: $3.6M • VOL: 41.1K
52W L $0 52W H $2
PMCB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-30 | FY 2024
FILED 2025-04-30 | FY 2023
FILED 2024-04-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.9M | -$4.4M | -$8.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$19.4M | $30.7M | $333.8K |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.2M | -$3.0M | -$2.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.2M | -$3.0M | -$2.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -30.2% | -14.5% | — |
| Cash & Short-Term Equivalents | $20.2M | $16.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $38.1M | $40.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PMCB.